Long-Term Treatment With Evolocumab Among Japanese Patients ― Final Report of the OSLER Open-Label Extension Studies ―
-
- Hirayama Atsushi
- Division of Cardiology, Osaka Police Hospital
-
- Yamashita Shizuya
- Departments of Community Medicine and Cardiovascular Medicine, Graduate School of Medicine, Osaka University Rinku General Medical Center
-
- Ruzza Andrea
- Amgen Inc.
-
- Inomata Hyoe
- Amgen Astellas BioPharma K.K.
-
- Cyrille Marcoli
- Amgen Inc.
-
- Lu Chen
- Amgen Inc.
-
- Hamer Andrew W.
- Amgen Inc.
-
- Yoshida Masayuki
- Life Science and Bioethics Research Center, Tokyo Medical and Dental University
-
- Kiyosue Arihiro
- Department of Cardiovascular Medicine, The University of Tokyo Hospital
-
- Teramoto Tamio
- Teikyo Academic Research Center, Teikyo University
Bibliographic Information
- Other Title
-
- LATE BREAKING CLINICAL TRIALS (JCS 2019) : Long-Term Treatment With Evolocumab Among Japanese Patients : Final Report of the OSLER Open-Label Extension Studies
Search this article
Description
<p>Background: Treatment with evolocumab reduces mean low-density lipoprotein cholesterol (LDL-C) up to 75% and cardiovascular events by 16% in the first year and 25% thereafter. </p><p>Methods and Results: Japanese patients with hypercholesterolemia enrolled in the parent YUKAWA-1-2 studies could enroll, once eligible, in the OSLER studies (n=556). OSLER re-randomized patients 2:1 to evolocumab plus standard of care (SOC; evolocumab+SOC) or SOC alone for 1 year; after year 1, patients could enter the all-evolocumab+SOC open-label extension of OSLER. Patients received evolocumab+SOC from the 2nd year through up to 5 years. Long-term efficacy and safety, including antidrug antibodies, were evaluated. Of 556 patients, 532 continued to the all-evolocumab+SOC extension: mean (standard deviation [SD]) age 61 (10) years, 39% female. A total of 91% of 532 patients completed the studies. Mean (SD) LDL-C change from parent-study baseline with evolocumab from a mean (SD) baseline of 142.3 (21.3) and 105.0 (31.1) mg/dL in OSLER-1 and OSLER-2, respectively, was maintained through the end of the study: −58.0% (19.1%) at year 5 in OSLER-1, −62.7% (25.6%) at year 3 in OSLER-2. The overall safety profile of the evolocumab+SOC periods was similar to that of the year-1 controlled period. Antidrug antibodies were detected transiently in 3 patients. No neutralizing antibodies were detected. </p><p>Conclusions: Japanese patients who continued evolocumab+SOC for up to 5 years experienced sustained high LDL-C level reduction. Long-term evolocumab+SOC exposure showed no new safety signals. </p>
Journal
-
- Circulation Journal
-
Circulation Journal 83 (5), 971-977, 2019-04-25
The Japanese Circulation Society
- Tweet
Details 詳細情報について
-
- CRID
- 1390564238088016896
-
- NII Article ID
- 130007636984
-
- NII Book ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- NDL BIB ID
- 029661286
-
- PubMed
- 30930429
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed